AstraZeneca shareholders urged to oppose pay plan for CEO Soriot Image Date Saturday, March 30, 2024 - 8:00 AM Description Shareholder advisory groups say potential £18.7mn payout is excessive
AstraZeneca shares fall as China probe intensifies Date Tuesday, November 05, 2024 - 11:33 AM Description Investigation of group’s China chief Leon Wang continues after several employees were found guilty of fraud
AstraZeneca signs deal for oral obesity drug and lifts profit outlook Date Thursday, November 09, 2023 - 3:38 AM Description Anglo-Swedish drugmaker’s oncology and rare disease medication sales offset waning demand for Covid jabs
AstraZeneca signs deal for oral weight loss drug and lifts profit outlook Date Thursday, November 09, 2023 - 2:34 AM Description Anglo-Swedish drugmaker’s oncology and rare disease medication sales offset waning demand for Covid-19 jabs
AstraZeneca strikes $1bn deal to acquire first vaccine company Date Tuesday, December 12, 2023 - 1:32 AM Description UK pharma group agrees to buy Seattle-based biotech Icosavax
AstraZeneca ties up with AI biologics company to develop cancer drug Date Saturday, December 02, 2023 - 10:00 PM Description Deal with Absci is the latest between big pharma and tech companies to build new disease treatments
AstraZeneca to build Chinese supply chain as US-Sino tensions increase Date Tuesday, May 21, 2024 - 10:30 AM Description Anglo-Swedish drugmaker targets $80bn in revenue by 2030
AstraZeneca unveils successes in treatment of lung cancer Date Monday, February 19, 2024 - 6:19 AM Description Best-selling Tagrisso drug slows progression of most common form of the disease at an early stage
AstraZeneca wrongfully dismissed senior scientist, tribunal finds Date Wednesday, January 31, 2024 - 8:27 AM Description James Muir was discriminated against on the basis of his mental health disability
AstraZeneca’s Soriot ‘massively underpaid’ at £16.9mn, says top shareholder Date Tuesday, April 09, 2024 - 11:00 AM Description GQG Partners argues that pharma group has performed strongly under long-serving chief